3D vertical-flow paper-based device for simultaneous detection of multiple cancer biomarkers by fluorescent immunoassay

Jiao, Yucui; Du, Chao; Zong, Lijun; Guo, Xueying; Han, Ya Fang; Zhang, Xiaopan; Li, Lin; Zhang, Chengwu; Ju, Qiang; Liu, Jinhua; Yu, Hai‐Dong; Huang, Wei

doi:10.1016/j.snb.2019.127239

Cited by 76 publications

(44 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many previous paper-based immunofluorescent assay studies also found the residue of antibody with fluorophore molecules in a negative sample. [18][19][20] An alternative way to minimize the background signal is to use black paper. [20] For clinical sample analysis such as human serum, plasma, etc., the background signal could be decreased by diluting the sample to minimize complex substance resulting in high background signal.…”

Section: Resultsmentioning

confidence: 99%

“…[18][19][20] An alternative way to minimize the background signal is to use black paper. [20] For clinical sample analysis such as human serum, plasma, etc., the background signal could be decreased by diluting the sample to minimize complex substance resulting in high background signal.…”

Section: Resultsmentioning

confidence: 99%

“…The linear range from our study is similar or better (100-fold concentration) than those of the reported values from paper-based fluorescent ELISA: Carcinoembryonic antigen (CEA) (0.1 -80 ng/mL), Alpha-fetoprotein (AFP) (0.1 -80 ng/mL), CA199 (0.1 -80 U/mL), Procalcitonin (PCT) (0.3 -200 ng/mL), C-reactive protein (CRP) (50-250 g/mL), and aflatoxin B1 (5 -150 pg/mL). [20][21][22] Recently, we reported a colorimetric paper-based ELISA for SARS-CoV-2 humanized antibody detection. The linear working range of antibody concentration (1 to 50 ng/µL) is similar to the fluorescent assay in this paper (0.5 to 50 ng/µL).…”

Section: Resultsmentioning

confidence: 99%

“…It is worth noting that the Gvalue from SARS-CoV-2 antibody spiked in PBS is higher than that of SARS-CoV-2 antibody spiked in human serum ratio of 1:100 dilution as impurity in human serum may increase background signal. In addition, known SARS-CoV-2 humanized antibody concentrations were prepared in human serum with ratio 1:100 dilution sample (5,10,20,50, and 100 ng/µL) Figure 6a depicts the bright green intensity versus the increasing antibody concentration. An increasing trend of Gvalue corresponds to the increase of SARS-CoV-2 humanized antibody concentration from 5 to 100 ng/µL (Figure 6b) The linear equation of fluorescent ELISA assay for SARS-CoV-2 humanized antibody concentration spiked in human serum with ratio of 1:100 dilution was fitted to be y = 0.3471x + 5.6771, with R2 = 0.962 with the data set of SARS-CoV-2 antibody concentration from 5 to 100 ng/µL (Figure 6c) These data advise that LOD of the assay for SARS-CoV-2 antibody spiked in human serum with ratio of 1:100 dilution is 10 ng/µL or 0.125 IU/mL.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

A Paper-based Immunofluorescent Device for the Detection of SARS-CoV-2 Humanized Antibody

Kasetsirikul¹,

Umer²,

Soda³

et al. 2021

Preprint

View full text Add to dashboard Cite

We report on an immunofluorescent paper-based assay for the detection of severe acute respiratory symptom coronavirus 2 (SARS-CoV-2) humanized antibody. The paper-based device was fabricated by using lamination technique for easy and optimized handling. Our approach utilises a two-step strategy that involves (i) initial coating of the paper-electrode with recombinant SARS-CoV-2 nucleocapsid antigen to capture the target SARS-CoV-2 specific antibodies, and (ii) subsequent detection of SARS-CoV-2 antibodies using fluorophore-conjugated IgG antibody. The fluorescence readout was observed with fluorescence microscopy. The images were processed and quantified using a MATLAB program. The assay can selectively detect SARS-CoV-2 humanized antibodies spiked in PBS and healthy human serum samples with the relative standard deviation of approximately 6.4% (for n = 3). It has broad dynamic ranges (1 ng to 50 ng/µL in PBS and 5 to 100 ng/µL in human serum samples) for SARS-CoV-2 humanized antibodies with the detection limits of 2 ng/µL (0.025 IU/mL) and 10 ng/µL (0.125 IU/mL) in PBS and human serum samples, respectively. We believe that our assay has the potential to be used as a simple, rapid, and inexpensive paper-based diagnostic device with a portable fluorescent reader to provide point-of-care diagnosis. This assay can be used for rapid examination of a large batch of samples toward clinical screening of SARS-CoV-2 specific antibodies as a confirmed infected active case or to evaluate the immune response to a SARS-CoV-2 vaccine.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

A Paper-based Immunofluorescent Device for the Detection of SARS-CoV-2 Humanized Antibody

Kasetsirikul¹,

Umer²,

Soda³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…In addition, the design of μPADs as multilayers and origami platforms can significantly improve the colorimetric signal for highly sensitive detection. Because the sample solution added onto multilayered μPADs can be automatically pretreated in the microfluidic channel before carrying out the colorimetric reactions at the detection zones, the color intensity and reproducibility are greatly increased [ 60 , 61 , 125 , 127 ]. Integrating colorimetric μPADs with cell culture microarrays has been developed for high-throughput drug screening.…”

Section: Detection Techniquesmentioning

confidence: 99%

Recent Advances in Microfluidic Paper-Based Analytical Devices toward High-Throughput Screening

et al. 2020

View full text Add to dashboard Cite

Microfluidic paper-based analytical devices (µPADs) have become promising tools offering various analytical applications for chemical and biological assays at the point-of-care (POC). Compared to traditional microfluidic devices, µPADs offer notable advantages; they are cost-effective, easily fabricated, disposable, and portable. Because of our better understanding and advanced engineering of µPADs, multistep assays, high detection sensitivity, and rapid result readout have become possible, and recently developed µPADs have gained extensive interest in parallel analyses to detect biomarkers of interest. In this review, we focus on recent developments in order to achieve µPADs with high-throughput capability. We discuss existing fabrication techniques and designs, and we introduce and discuss current detection methods and their applications to multiplexed detection assays in relation to clinical diagnosis, drug analysis and screening, environmental monitoring, and food and beverage quality control. A summary with future perspectives for µPADs is also presented.

show abstract

Advances in Multiplexed Paper‐Based Analytical Devices for Cancer Diagnosis: A Review of Technological Developments

Yönet-Tanyeri

Ahlmark

Little

2021

Adv Materials Technologies

View full text Add to dashboard Cite

Cancer is one of the leading causes of death worldwide producing an estimated cost of $161.2 billion in the US in 2017 only. Early detection of cancer can not only reduce cancer mortality rates but also dramatically reduce healthcare costs given that the 17 million new cancer cases in 2018 are estimated to grow 27.5 million new cases by 2040. Analytical devices based upon paper substrates can provide effective, rapid, and extremely low‐cost alternatives for early cancer detection compared to existing testing methods. However, low concentrations of biomarkers in body fluids as well as the possible association of any given biomarker with multiple diseases remains one of the greatest challenges to widespread adoption of these paper‐based devices. Fortunately, recent advances have opened the possibility of detecting multiple biomarkers within the same device, which can be predictive of a patient's condition with unprecedented cost‐effectiveness. Accordingly, this review highlights the recent advancements in paper‐based analytical devices with a multiplexing focus. The primary areas of interest include lateral flow assay and microfluidic paper‐based assay formats, signal amplification approaches to enhance the sensitivity for a specific cancer type, along with current challenges and future outlook for the detection of multiple cancer biomarkers.

show abstract

3D vertical-flow paper-based device for simultaneous detection of multiple cancer biomarkers by fluorescent immunoassay

Cited by 76 publications

References 60 publications

A Paper-based Immunofluorescent Device for the Detection of SARS-CoV-2 Humanized Antibody

A Paper-based Immunofluorescent Device for the Detection of SARS-CoV-2 Humanized Antibody

Recent Advances in Microfluidic Paper-Based Analytical Devices toward High-Throughput Screening

Advances in Multiplexed Paper‐Based Analytical Devices for Cancer Diagnosis: A Review of Technological Developments

Contact Info

Product

Resources

About